Blue Earth Diagnostics Announces Positive Results from Prostate Cancer Imaging Study

Head-to-head comparison shows POSLUMA has significantly lower urinary radioactivity than piflufolastat F 18

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Blue Earth Diagnostics, a Bracco company, announced positive results from a head-to-head study comparing the urinary bladder radioactivity and lesion detection rates of its POSLUMA (flotufolastat F 18) PET radiopharmaceutical and piflufolastat F 18 in men with low prostate-specific antigen (PSA) biochemical recurrence of prostate cancer following radical prostatectomy. The study met its primary endpoint, demonstrating statistically significant lower urinary bladder radioactivity with POSLUMA compared to piflufolastat F 18. Secondary analyses also showed higher patient-level and region-level detection rates with POSLUMA, including among patients with very low PSA levels.

Why it matters

Biochemical recurrence after prostate cancer surgery can be an early sign that the cancer has returned, even before it is visible on conventional imaging. PET tracers that can clearly show small areas of recurrent disease at very low PSA levels may support earlier and more informed clinical care decisions for these patients.

The details

The prospective, multicenter, intra-patient study evaluated 55 patients with biochemical recurrence and PSA levels ≤0.5 ng/mL. The primary endpoint was the difference in bladder standardized uptake value (SUV) between POSLUMA and piflufolastat F 18, with POSLUMA demonstrating significantly lower urinary radioactivity. Secondary analyses showed higher detection rates with POSLUMA, including in the prostate bed and extra-pelvic regions, and among patients with very low PSA levels (≤0.2 ng/mL).

  • The study results were published in the European Journal of Nuclear Medicine and Molecular Imaging and presented at the 2026 ASCO Genitourinary Cancers Symposium on February 26, 2026.

The players

Blue Earth Diagnostics

A growing international molecular imaging company focused on delivering innovative diagnostic solutions that inform patient care. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A.

Dr. Eugene Teoh

Chief Medical Officer of Blue Earth Diagnostics.

Phillip Kuo

Founder of Kuo Radiology LLC.

Got photos? Submit your photos here. ›

What they’re saying

“For men who have already undergone surgery for prostate cancer, a rising PSA can be deeply concerning, especially when conventional imaging cannot clearly show whether or where the disease has returned. This head-to-head study provides important clinical evidence from a rigorous intra-patient comparison, demonstrating that POSLUMA exhibits significantly lower urinary radioactivity while maintaining meaningful detection capability in men with early biochemical recurrence.”

— Dr. Eugene Teoh, Chief Medical Officer of Blue Earth Diagnostics (Press Release)

“This rigorous head-to-head study provides high quality evidence that POSLUMA has significantly lower urinary bladder radioactivity compared to piflufolastat F 18, confirming prior studies. POSLUMA also exhibited higher detection rates for recurrence compared to piflufolastat F 18, which highlights its potential to improve patient management.”

— Phillip Kuo, Founder of Kuo Radiology LLC (Press Release)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This study highlights the potential for POSLUMA, a PSMA-targeted PET radiopharmaceutical, to improve imaging and management of men with biochemical recurrence of prostate cancer by demonstrating significantly lower urinary radioactivity compared to another PSMA tracer, which can help optimize image assessment in anatomically challenging regions.